TOKYO, May 11 /CNW/ - Sosei Group Corporation ("Sosei"; TSE Mothers
Index: 4565), the biopharmaceutical company, today announces that Sosei
Co., Ltd., its wholly owned Japanese subsidiary, acquired development
and commercialization rights to Loramyc(R) (miconazole Lauriad(R).
Sosei development code: SO-1105) in Japan from BioAlliance Pharma.
Loramyc(R) is an antifungal agent, administered as a muco-adhesive
buccal tablet for the treatment of oropharyngeal candidiasis in
immunocompromised patients. BioAlliance received its first Loramyc(R)
marketing authorization in France in October 2006. Loramyc(R) has since
been registered in 26 European countries, in South Korea, and in the
Under the terms of the agreement, Sosei will pay BioAlliance an upfront
license fee of $3 million and further development and sales-based
milestones totaling up to a maximum of $18.5 million. Sosei will also
pay royalties on net sales of the product.
By acquiring development and commercialization rights to Loramyc(R)
Sosei will broaden its development pipeline and continue with its
strategy of bringing products that are in the late stage of development
or already marketed in the West to Japan.
Shinichi Tamura, CEO of Sosei Group Corporation, commented: "We are very
pleased to be teaming up with BioAlliance Pharma on this innovative
product. Loramyc(R) has the potential to become the first treatment in
tablet form for oropharyngeal candidiasis in Japan, to provide an
important addition to available treatments, and to enhance patients'
compliance and improve their quality of life."
Notes for Editors:
About Oropharyngeal Candidiasis
Fungal infections of the oral mucosa are most frequently caused by
Candida species, with C. albicans being the most common species
associated with such infections. Oropharyngeal candidiasis is commonly
found in immuno-compromised patients, including HIV and cancer
patients, and in other chronic disease states such as diabetes. For
instance, oropharyngeal candidiasis is the most frequently occurring
infection in head and neck cancer patients undergoing radiation
therapy. The clinical presentation of oropharyngeal candidiasis is
variable with symptoms including soreness, burning, and/or altered
taste. The signs of clinical candidiasis usually include white
pseudomembraneous plaques and patches (thrush), erythematous lesions or
occasionally angular cheilitis. Left untreated, the condition may
progress to involve the esophagus or to more serious systemic
Sosei is an international biopharmaceutical company anchored in Japan
with a global reach. It practises a reduced risk business model by
acquiring compounds from, and bringing compounds into, Japan through
exploitation of its unique position within global markets.
For further information about Sosei, please visit http://www.sosei.com.
About BioAlliance Pharma
Dedicated to cancer and supportive care - cancer related pathologies,
chemotherapy and radiotherapy-induced complications and opportunistic
infections in immunocompromised patients - BioAlliance conceives and
develops innovative products, especially in the hospital setting and
for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005,
BioAlliance Pharma's ambition is to become a leading player in these
fields by coupling innovation to patient needs. The company's teams
have the key competencies required to identify, develop and register
drugs in Europe and the USA; the products' commercialization rights are
licensed to international commercial partners invested in the hospital
setting. In areas where medical needs are insufficiently met, its
targeted approaches help overcome drug resistance and improve patient
health & quality of life.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc(R)/Oravig(R) (oropharyngeal candidiasis in immunocompromised
patients): Registered in 26 European countries, in Korea and in the
Setofilm(R) (prevention and treatment of -chemotherapy, radiotherapy and
post operative- induced nausea and vomiting in adults and children):
Registered in 16 European countries
Sitavir(TM) (Acyclovir Lauriad TM) (labialis herpes): Positive phase III
final results; registration status
Fentanyl LauriadTM (chronic cancer pain): Positive preliminary Phase I
AMEP(R) (invasive melanoma): Phase I
Clonidine LauriadTM (mucositis): Phase II
Doxorubicin Transdrug(R) (liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at http://www.bioalliancepharma.com
SOURCE Sosei Group Corporation
For further information:
Sosei Group Corporation, Tokyo Office: Milica STOJKOVIC, Investor Relations, +81-(0)3-5210-3399, email@example.com; London Office: Kathryn LYDON, PA to CEO & Corporate Communication, +44-(0)20-7691-0983, KLydon@sosei.com